Cargando…

Rationale, Strengths, and Limitations of Real-World Evidence in Oncology: A Canadian Review and Perspective

Randomized controlled trials (RCTs) continue to be the basis for essential evidence regarding the efficacy of interventions such as cancer therapies. Limitations associated with RCT designs, including selective study populations, strict treatment regimens, and being time-limited, mean they do not pr...

Descripción completa

Detalles Bibliográficos
Autor principal:	Azoulay, Laurent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Health Outcomes and Economics of Cancer Care
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438907/ https://www.ncbi.nlm.nih.gov/pubmed/35762676 http://dx.doi.org/10.1093/oncolo/oyac114

Ejemplares similares

Real‐World Clinical and Economic Outcomes in Selected Immune‐Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors
por: Zheng, Ying, et al.
Publicado: (2021)

Real‐World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B‐Cell Lymphoma in the U.S
por: Yang, Xiaoqin, et al.
Publicado: (2021)

The Value of Pharmaceutical Industry-Sponsored Patient Registries in Oncology Clinical Research
por: Flick, E Dawn, et al.
Publicado: (2023)

Analysis of Female Participant Representation in Registered Oncology Clinical Trials in the United States from 2008 to 2020
por: Perera, Nirosha D, et al.
Publicado: (2023)

Using Patient-Reported Outcomes in Dose-Finding Oncology Trials: Surveys of Key Stakeholders and the National Cancer Research Institute Consumer Forum
por: Lai-Kwon, Julia, et al.
Publicado: (2022)

Temporal Trends in Inpatient Oncology Census Before and During the COVID‐19 Pandemic and Rates of Nosocomial COVID‐19 Among Patients with Cancer at a Large Academic Center
por: Zubiri, Leyre, et al.
Publicado: (2021)

Access to and Affordability of World Health Organization Essential Medicines for Cancer in Sub-Saharan Africa: Examples from Kenya, Rwanda, and Uganda
por: Kizub, Darya A, et al.
Publicado: (2022)

Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration
por: Chan, Kelvin, et al.
Publicado: (2020)

Individual Trade‐Offs Between Possible Benefits and Risks of Cancer Treatments: Results from a Stated Preference Study with Patients with Multiple Myeloma
por: Postmus, Douwe, et al.
Publicado: (2017)

Costs of Cancer Care Across the Disease Continuum
por: Kaye, Deborah R., et al.
Publicado: (2018)

Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis
por: Choi, Jin G., et al.
Publicado: (2018)

Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study)
por: McArthur, Grant A., et al.
Publicado: (2017)

Multiple Myeloma Incidence and Mortality Around the Globe; Interrelations Between Health Access and Quality, Economic Resources, and Patient Empowerment
por: Ludwig, Heinz, et al.
Publicado: (2020)

Women Who Are Young, Non‐White, and with Lower Socioeconomic Status Report Higher Financial Toxicity up to 1 Year After Breast Cancer Surgery: A Mixed‐Effects Regression Analysis
por: Politi, Mary C., et al.
Publicado: (2020)

Relative Dose Intensity of Chemotherapy and Survival in Patients with Advanced Stage Solid Tumor Cancer: A Systematic Review and Meta‐Analysis
por: Nielson, Carrie M., et al.
Publicado: (2021)

COVID-19 Outcomes Among Patients With Cancer: Observations From the University of California Cancer Consortium COVID-19 Project Outcomes Registry
por: Borno, Hala T, et al.
Publicado: (2022)

“Game Changer”: Health Professionals’ Views on the Clinical Utility of Circulating Tumor DNA Testing in Hereditary Cancer Syndrome Management
por: Shickh, Salma, et al.
Publicado: (2022)

Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID‐19
por: Klein, Isaac A., et al.
Publicado: (2021)

The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint Inhibitors
por: George, Saby, et al.
Publicado: (2021)

Improved Survival of Young Adults with Cancer Following the Passage of the Affordable Care Act
por: Roth, Michael, et al.
Publicado: (2022)

Treatment Patterns, Health Care Resource Utilization, and Cost in Patients with Myelofibrosis in the United States
por: Copher, Ronda, et al.
Publicado: (2022)

Impact of Immune Checkpoint Inhibitors on COVID-19 Severity in Patients with Cancer
por: Tan, Ruoding, et al.
Publicado: (2022)

Utilization of Immunotherapy in Patients with Cancer Treated in Routine Care Settings: A Population-Based Study Using Health Administrative Data
por: Raphael, Jacques, et al.
Publicado: (2022)

Physician Payments from Pharmaceutical Companies Related to Cancer Drugs
por: Mitchell, Aaron P, et al.
Publicado: (2022)

The Use of Natural Language Processing to Assess Social Support in Patients With Advanced Cancer
por: Bhatt, Sunil, et al.
Publicado: (2022)

Contact Days Associated With Cancer Treatments in the CCTG LY.12 Trial
por: Gupta, Arjun, et al.
Publicado: (2023)

Development and Validation of a High‐Quality Composite Real‐World Mortality Endpoint
por: Curtis, Melissa D., et al.
Publicado: (2018)

ASH Research Collaborative: a real-world data infrastructure to support real-world evidence development and learning healthcare systems in hematology
por: Wood, William A., et al.
Publicado: (2021)

Estimated mortality rates of individuals with sickle cell disease in Brazil: real-world evidence
por: Cançado, Rodolfo Delfini, et al.
Publicado: (2023)

Diagnosis and Management of Oncologic Emergencies
por: Klemencic, Sarah, et al.
Publicado: (2019)

Results of VOICE: a global survey of disease-specific knowledge and perspectives of real-world patients with CLL
por: Tam, Constantine, et al.
Publicado: (2023)

New Frameworks to Assess Value of Cancer Care: Strengths and Limitations
por: Schnipper, Lowell E., et al.
Publicado: (2016)

Cost-effectiveness of ablation of ventricular tachycardia in ischaemic cardiomyopathy: limitations in the trial evidence base
por: Chen, Yang, et al.
Publicado: (2020)

Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia
por: Roeker, Lindsey E., et al.
Publicado: (2023)

Relationships between hyperinsulinaemia, magnesium, vitamin D, thrombosis and COVID-19: rationale for clinical management
por: Cooper, Isabella D, et al.
Publicado: (2020)

PRospective Evaluation of natriuretic peptide-based reFERral of patients with chronic heart failure in primary care (PREFER): a real-world study
por: Hobbs, FD Richard, et al.
Publicado: (2021)

Evidence-Based Heatstroke Management in the Emergency Department
por: Rublee, Caitlin, et al.
Publicado: (2021)

Perspectives on Home-based Healthcare as an Alternative to Hospital Admission After Emergency Treatment
por: Stuck, Amy, et al.
Publicado: (2017)

Limitations of transoesophageal echocardiogram in acute ischaemic stroke
por: Rosol, Zachary P, et al.
Publicado: (2020)

The cost-effectiveness of initiating ranibizumab therapy in eyes with neovascular AMD with good vision: an economic model using real-world outcomes
por: Butt, Thomas, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_e15c5m7dugkcgv0l2jlh4sr4l3